.jpg)
Plant-Based Vaccines and Biologics Offer Continue Low-Cost Health Security
The Challenge
- Africa produces less than 1% of the world’s total vaccine supply1.
- African countries are vulnerable to vaccine shortages and global supply
chain disruptions. - Research institutions in southern Africa hold a large portfolio of plant-based vaccine patents, but are struggling to bridge the gap to clinical trials and large-scale vaccine manufacture.
- Plant-based vaccines offer an agile, low-cost technology that could boost
local manufacturing and strengthen existing healthcare systems and future pandemic preparedness.
Please download the STEM Impact Memo below to find out more
Launch Event
The memo was launched officially at an event at the 12th African Congress of Immunology, December 2024.
Authors
Faith Osier
Director, Chanjo Hub and Co-Director,
Institute of Infection, Imperial College London, UK
Tsepo Tsekoa
Chief Researcher and Research Group Leader,
CSIR Chemicals Cluster, Zambia
David Jarvis
Chief Technology Officer, Liselo Labs, South Africa